



**Oramed Pharmaceuticals Inc.**  
**1185 Avenue of the Americas**  
**New York, NY 10036**  
**Phone: 1 844 9 ORAMED**  
**www.oramed.com**

## COMPANY OVERVIEW

- Breakthrough platform technology for oral delivery of drugs and vaccines presently available only via injection
- Pipeline currently focused on diabetes, with potential for a variety of additional treatment indications addressing multi-billion-dollar markets
- Positive results from oral insulin (ORMD-0801) pivotal Phase 2b study
- Phase 3 studies under US FDA
- Oramed’s lead product, oral insulin, has potential to be the first commercial oral insulin
- Robust worldwide patent portfolio protection

## EQUITY OVERVIEW

(as of 22/Oct/20)

Nasdaq/TASE: ORMP

Price: ~\$2.55

Market Cap: \$60 M

52 Week Range: \$2.32-\$6.05

Avg. Daily Volume (90 day): 135 K

Shares Outstanding: 23.3 M

Cash/Investments: \$45.6 M (as of 5/31/20)

## ANALYST COVERAGE

- H.C. Wainwright & Co.
- Ladenburg Thalmann
- Aegis Capital
- Zacks

## BETTER WAY TO TREAT DIABETES

**1 in 11 adults  
on the planet has  
diabetes**

**1** healthcare  
**in 8**  
Is spent on diabetes



## INVESTMENT HIGHLIGHTS

### Breakthrough Platform Technology Delivers Injectable Drugs Orally

Oramed’s unique Protein Oral Delivery (POD™) technology enables small proteins such as insulin to travel through the gastrointestinal tract and into the bloodstream. This method is more natural and should eliminate many of the negative side-effects of injection delivery. The oral administration of current injection-only therapies for conditions including diabetes should offer clear benefits including increased compliance and safety, fewer side effects and greater comfort for patients.

### Addressing \$70 Billion Market with Oral Formulations

Roughly \$70 billion worth of drugs and vaccines are currently delivered via injection. This includes the diabetes market where \$24 billion of insulin and \$6 billion of GLP-1 analogs were sold globally in 2017. The vaccine market size was approximately \$33.6 billion in 2017 and is expected to surpass \$103.6 billion by 2028.

### Oral Treatment has the Potential to Curb Progression of Type 2 Diabetes

ORMD-0801 has the potential to create a new paradigm in the treatment of type 2 diabetes by orally delivering insulin at an earlier stage of treatment. Earlier treatment can potentially slow disease progression and delay late-stage complications. Oramed successfully completed a 90-day HbA1c study of ORMD-0801, which met its primary endpoint achieving a statistically significant reduction of HbA1c. Oramed is initiating Phase 3 studies under the FDA, and is pursuing a Biologics License Application (BLA) regulatory pathway for ORMD-0801 which would grant a full 12 years of marketing exclusivity, if approved.

### Oral GLP-1 Analog to Stimulate Insulin Production in Type 2 Diabetes

Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. It is beneficial to type 2 diabetic patients by promoting weight loss and decreasing blood glucose. Oramed’s ORMD-0901, an oral GLP-1 analog completed small clinical trials with encouraging results it is currently in the midst of a bioavailability study in the US.

## 2020 ANTICIPATED UPCOMING MILESTONES

ORMD-0801: Oral Insulin	➤ Initiate Phase 3 in diabetes patients ➤ Initiate Part 2 of NASH exploratory study
ORMD-0901: Oral GLP-1	➤ Initiate bioavailability study in diabetes patients
Oral Leptin	➤ Phase 1 initiation